People News: Alexion Pharmaceuticals and KV Pharmaceutical
Specialty firm KV Pharmaceutical named David Van Vliet CEO, with a term through December 31, 2011. Van Vliet has served as interim president and CEO since December 2008.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.
Hires and promotions for Manufacturers, Agencies and Media